EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

National drug utilisation patterns of antithrombotic and anti-inflammatory therapies: a cross-national comparison between Switzerland and Germany

Michael Kunz, Marita Kieble, Andrea Espinosa Daudí, Lucas Lauder, Ulrich Laufs, Felix Götzinger, Jasper Boeddinghaus iD, Gregor Leibundgut, Christoph R Meier, Christian Mueller iD, Martin Schulz, Felix Mahfoud iD

Swiss Medical Weekly · 16.11.2026 · 156 (11) · 5371

DOI: 10.57187/5371 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Swiss Medical Weekly, online erschienen am 16.11.2026. Verfasst von Michael Kunz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Cardiology, University Heart Center Basel, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Anti-Inflammatory Agents, Drug Utilization. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY AIMS: Prolonged low-dose antithrombotic and anti-inflammatory therapies have been shown to reduce cardiovascular events and are guideline-recommended in patients with coronary artery disease at high ischaemic risk. However, their real-world dispensing patterns at the population level remain insufficiently characterised. This study aimed to quantify national dispensing volumes and compare the use of these therapies in Switzerland and Germany between 2022 and 2024. METHODS: We analysed national pharmaceutical delivery data from Switzerland and outpatient prescription data from Germany for low-dose monotherapy products containing aspirin (100 mg), clopidogrel (75 mg), prasugrel (5 mg and 10 mg), ticagrelor (60 mg and 90 mg), rivaroxaban (2.5 mg) and colchicine (0.5 mg in Germany, 1 mg in Switzerland). Drug utilisation was standardised as the number of tablets per 1000 persons per year. This metric reflects population-level exposure: based on epidemiological data indicating a substantial burden of cardiovascular disease and evidence that a relevant proportion of these patients may qualify for intensified long-term preventive therapy, dispensing volumes of long-term antithrombotic and anti-inflammatory therapies might be expected to reach a meaningful fraction of aspirin use (>10%). Values substantially below this illustrative threshold may suggest limited population-level uptake. RESULTS: Aspirin 100 mg was the most frequently dispensed drug in both Switzerland and Germany (both >8000 tablets/1000 persons/year). Clopidogrel ranked second in both countries. Ticagrelor (60 mg and 90 mg) was more frequently dispensed in Switzerland, whereas prasugrel 10 mg was more frequently dispensed in Germany. However, absolute use of both agents remained low (all

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsAnti-Inflammatory AgentsDrug UtilizationHumansSwitzerlandGermanyAspirinPrasugrel HydrochlorideRivaroxabanClopidogrelTicagrelorPlatelet Aggregation InhibitorsCardiovascular DiseasesFemale

Substanzen

Fibrinolytic AgentsAnti-Inflammatory AgentsAspirinPrasugrel HydrochlorideRivaroxabanClopidogrelTicagrelorPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Clinic of Cardiology, University Heart Center Basel, University Hospital Basel, Basel, Switzerland.
  • Cardiovascular Research Institute Basel (CRIB), Basel, Switzerland.
  • German Institute for Drug Use Evaluation (DAPI), Berlin, Germany.
  • Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany.
  • Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.

ORCID-Profile: Jasper Boeddinghaus, Christian Mueller, Felix Mahfoud

Zitieren

APA

Kunz, M., Kieble, M., Espinosa Daudí, A., Lauder, L., Laufs, U., Götzinger, F., Boeddinghaus, J., Leibundgut, G., Meier, C. R., Mueller, C., Schulz, M., & Mahfoud, F. (2026). National drug utilisation patterns of antithrombotic and anti-inflammatory therapies: a cross-national comparison between Switzerland and Germany. Swiss Medical Weekly, 156(11), 5371. https://doi.org/10.57187/5371

Vancouver

Kunz M, Kieble M, Espinosa Daudí A, Lauder L, Laufs U, Götzinger F, et al. National drug utilisation patterns of antithrombotic and anti-inflammatory therapies: a cross-national comparison between Switzerland and Germany. Swiss Medical Weekly. 2026;156(11):5371. doi:10.57187/5371

BibTeX
@article{Kunz2026,
  author = {Kunz, Michael and Kieble, Marita and Espinosa Daudí, Andrea and Lauder, Lucas and Laufs, Ulrich and Götzinger, Felix and Boeddinghaus, Jasper and Leibundgut, Gregor and Meier, Christoph R and Mueller, Christian and Schulz, Martin and Mahfoud, Felix},
  title = {National drug utilisation patterns of antithrombotic and anti-inflammatory therapies: a cross-national comparison between Switzerland and Germany},
  journal = {Swiss Medical Weekly},
  year = {2026},
  volume = {156},
  number = {11},
  pages = {5371},
  doi = {10.57187/5371}
}
Kostenlos starten →